insights_auto
Mtazamo: Thamani itaongezeka kwa asilimia 50.0·Thamani itapungua kwa asilimia 5.0
Nenda kwenye kichupo cha uchanganuzichevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$Â 14.51
arrow_upward
+0.07%(+0.010) Siku 1
US$Â 14.52
arrow_upward
+0.07% (+0.010)bedtimeBaada ya saa
Imefungwa: 18 Sep, 16:00:01 GMT -4 · USD
search
Alama zote
Siku 1
Siku 5
Mwezi 1
Miezi 6
YTD
Mwaka 1
Miaka 5
ISIZIDI
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya RARE...
Fungua
US$Â 14.79
Juu
US$Â 15.07
Chini
US$Â 14.07
Mtaji wa soko
1.43B
Wastani wa kiasi cha mauzo
4.40M
Kiasi cha mauzo ya hisa
13.34M
Juu kwa wiki 52
US$Â 39.89
Chini kwa wiki 52
US$Â 12.73
EPS
-US$Â 5.84
Beta
0.32
Hisa za wawekezaji
98.59M
Idadi ya wafanyakazi
elfu 1
Fungua
US$Â 14.79
Juu
US$Â 15.07
Chini
US$Â 14.07
Mtaji wa soko
1.43B
Wastani wa kiasi cha mauzo
4.40M
Kiasi cha mauzo ya hisa
13.34M
Juu kwa wiki 52
US$Â 39.89
Chini kwa wiki 52
US$Â 12.73
EPS
-US$Â 5.84
Beta
0.32
Hisa za wawekezaji
98.59M
Idadi ya wafanyakazi
elfu 1
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
AD HOC NEWS
·
saa 18 zilizopita
Ultragenyx Pharmaceutical stock gains after FDA approval and fresh analyst targets
Zacks
·
siku 1 iliyopita
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Benzinga
·
siku 2 zilizopita
Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest
Investing.com
·
siku 2 zilizopita
FDA approves Ultragenyx gene therapy for rare disorder MPS IIIA
Wasifu
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Kuhusu Ultragenyx Pharmaceutical Inc
Afisa Mkuu Mtendaji (CEO)Emil Kakkis
Wafanyakazielfu 1.37
Lilianzishwa2010
Makao makuuNovato, California, Marekani
Sekta-
Tovutiultragenyx.com